Bausch Health Companies Sees Unusually High Options Volume (NYSE:BHC)

Bausch Health Companies Inc. (NYSE:BHC - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors bought 6,028 call options on the stock. This represents an increase of 54% compared to the typical volume of 3,912 call options.

Bausch Health Companies Stock Performance

Shares of BHC traded down $0.27 during midday trading on Friday, hitting $6.49. The company had a trading volume of 1,357,833 shares, compared to its average volume of 2,769,308. Bausch Health Companies has a 1 year low of $3.96 and a 1 year high of $11.46. The company's 50-day simple moving average is $7.07 and its 200-day simple moving average is $7.72. The firm has a market capitalization of $2.39 billion, a P/E ratio of -54.04, a P/E/G ratio of 0.37 and a beta of 0.59.

Bausch Health Companies (NYSE:BHC - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.44). The firm had revenue of $2.56 billion for the quarter, compared to analysts' expectations of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. Equities analysts predict that Bausch Health Companies will post 4.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on BHC. Jefferies Financial Group reissued a "hold" rating and issued a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. Royal Bank of Canada dropped their price objective on shares of Bausch Health Companies from $11.00 to $10.00 and set a "sector perform" rating for the company in a report on Thursday, January 30th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $7.42.

Remove Ads

Institutional Investors Weigh In On Bausch Health Companies

Institutional investors have recently added to or reduced their stakes in the business. Mountain Hill Investment Partners Corp. purchased a new position in shares of Bausch Health Companies in the 4th quarter valued at $56,000. Bank of Nova Scotia acquired a new stake in shares of Bausch Health Companies during the fourth quarter worth about $83,000. One68 Global Capital LLC purchased a new stake in shares of Bausch Health Companies in the 4th quarter valued at about $90,000. Balyasny Asset Management L.P. purchased a new position in Bausch Health Companies during the 4th quarter worth approximately $97,000. Finally, Alpine Global Management LLC purchased a new position in Bausch Health Companies during the 4th quarter worth approximately $114,000. Hedge funds and other institutional investors own 78.65% of the company's stock.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.